Inhibikase Therapeutics, Inc.

NasdaqCM:IKT Stock Report

Market Cap: US$13.8m

Inhibikase Therapeutics Future Growth

Future criteria checks 2/6

Inhibikase Therapeutics is forecast to grow earnings and revenue by 25.2% and 73.2% per annum respectively while EPS is expected to grow by 43% per annum.

Key information

25.2%

Earnings growth rate

43.0%

EPS growth rate

Biotechs earnings growth20.7%
Revenue growth rate73.2%
Future return on equityn/a
Analyst coverage

Low

Last updated20 Feb 2024

Recent future growth updates

Recent updates

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Jan 25
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Aug 26

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Aug 12

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Aug 09
Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06
Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Inhibikase Therapeutics prices stock offering at $3

Jun 16

Earnings and Revenue Growth Forecasts

NasdaqCM:IKT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20269-25-28-222
12/31/2025N/A-27-32-212
12/31/2024N/A-22-24-192
12/31/20230-20-20-192
9/30/20230-19-18-18N/A
6/30/20230-19-20-20N/A
3/31/20230-18-20-19N/A
12/31/20220-18-18-17N/A
9/30/20220-19-18-18N/A
6/30/20220-19-14-14N/A
3/31/20222-17-14-14N/A
12/31/20213-15-14-14N/A
9/30/20213-11-11-11N/A
6/30/20213-7-9-9N/A
3/31/20212-5-5-5N/A
12/31/20201-3-1-1N/A
9/30/20201-200N/A
6/30/20201-300N/A
3/31/20201-500N/A
12/31/20191-600N/A
9/30/20192-711N/A
3/31/20194-400N/A
12/31/20184-211N/A
9/30/20183-100N/A
3/31/20183000N/A
12/31/20172000N/A
12/31/20161-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IKT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IKT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IKT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IKT's revenue (73.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: IKT's revenue (73.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IKT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.